BridgeMD
Compares treatment options for Siewert Type II Adenocarcinoma of Esophagogastric Junction
Official title Right Versus Left Thoracic Surgical Approaches for Siewert II Gastroesophageal Junction Adenocarcinoma
ClinicalTrials.gov ID: NCT06644352
What this study is testing
- What it's testing
- To explore the 5-year overall survival (OS) of right versus left thoracic surgical approaches for patients with locally advanced Siewert II gastroesophageal junction adenocarcinoma treated by neoadjuvant chemotherapy
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 80
You may be able to join if
- Histologically confirmed gastroesophageal adenocarcinoma;
- R0 resectable Siewert Ⅱ, cT2-3N0-3M0 (AJCC V8 TNM classification);
- Have a performance status of 0 or 1 on the ECOG Performance Scale;
- Age 18-80 years old, both men and women;
- Estimated survival ≥6 months;
You likely can't join if
- Have a history of other malignant tumors in the past or at the same time;
- Previous upper abdominal surgery (excluding cholecystectomy);
- Bleeding, perforation and obstruction requiring emergency surgical treatment;
- Severe heart, lung, liver and kidney dysfunction, which the researcher thinks is not suitable for operation;
- Hydrothorax and ascites with clinical symptoms need therapeutic puncture or drainage;
- Participate in other clinical studies or less than 1 month from the end of the previous clinical study;
See the full eligibility criteria
- Histologically confirmed gastroesophageal adenocarcinoma;
- R0 resectable Siewert Ⅱ, cT2-3N0-3M0 (AJCC V8 TNM classification);
- Have a performance status of 0 or 1 on the ECOG Performance Scale;
- Age 18-80 years old, both men and women;
- Estimated survival ≥6 months;
- Be willing and able to provide written informed consent/assent for the trial;
- Demonstrate adequate organ function ;
- Female subject of childbearing potential should have a negative urine or serum pregnancy within 7 days before enrollment. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be...
- Have not received systemic or local treatment for esophageal cancer in the past.
- Have a history of other malignant tumors in the past or at the same time;
- Previous upper abdominal surgery (excluding cholecystectomy);
- Bleeding, perforation and obstruction requiring emergency surgical treatment;
- Severe heart, lung, liver and kidney dysfunction, which the researcher thinks is not suitable for operation;
- Hydrothorax and ascites with clinical symptoms need therapeutic puncture or drainage;
- Participate in other clinical studies or less than 1 month from the end of the previous clinical study;
- Have a history of psychoactive drug abuse, alcoholism or drug abuse;
- Be unable or do not agree to bear the inspection and treatment expenses at their own expense;
- The researcher thinks that it should be excluded from this study.
The study team makes the final eligibility decision.
Where it's taking place
- Beijing, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 80 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Beijing, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.